p70 S6K

The reduction in UACR from baseline to month 4 was greater with finerenone compared with placebo (31% reduction), and the incidence of the secondary composite kidney outcome (kidney failure, sustained decrease of 57% in the eGFR from baseline [consistent with a doubling of serum creatinine], or death from kidney causes) occurred in fewer patients in the finerenone group (252 patients [8

The reduction in UACR from baseline to month 4 was greater with finerenone compared with placebo (31% reduction), and the incidence of the secondary composite kidney...